News

Seven Bridges, the industry-leading bioinformatics ecosystem provider, is supporting Pfizer Inc. in the development of a data management and collaboration solution for the…
Read More...

Altasciences is pleased to have contributed to the recent FDA approval of Vibegron, by performing three early phase clinical trials. Vibegron is a beta-3 adrenergic receptor (β3)…
Read More...

Crown Bioscience (CrownBio), JSR Life Sciences and Cambridge Quantum Computing (CQC) today announced a partnership agreement to explore the application of quantum technology to drive…
Read More...

QIAGEN and INOVIO Pharmaceuticals announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products…
Read More...

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review the company’s Biologics License Application (BLA) for TicoVac, its tick-borne…
Read More...

Adaptive Biotechnologies Corporation a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and…
Read More...

UCB and Microsoft have announced a new multi-year, strategic collaboration to combine Microsoft's computational services, cloud, and artificial intelligence (AI) with UCB's drug…
Read More...

SIRION Biotech GmbH, a world leader in viral vector-based gene delivery technologies for gene & cell therapy, announced that it signed a license and collaboration agreement with…
Read More...

Compugen Ltd. a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, announced the expansion of its clinical collaboration agreement with Bristol…
Read More...

On February 21, 2021, GenScript ProBio and SunRock Biopharma, a company focused on the development of antibody therapeutics targeting cancer, announced a collaboration spanning…
Read More...

Novavax, Inc. a biotechnology company developing next-generation vaccines for serious infectious diseases, announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in…
Read More...

Sanofi and GlaxoSmithKline (GSK) announced the initiation of a new Phase 2 study with 720 volunteers aged 18 and over to select the most appropriate antigen dosage for Phase 3…
Read More...

AstraZeneca announced the voluntary withdrawal of the Imfinzi (durvalumab) indication in the US for previously treated adult patients with locally advanced or metastatic bladder cancer.…
Read More...

Covectra, a leader in track and trace solutions, announced the next generation of StellaGuard, a smart label and mobile authentication solution that will enable brand managers and…
Read More...

Junshi Biosciences a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, announced that the National…
Read More...

Pfizer Inc. and BioNTech SE announced that the first participants have been dosed in a global Phase 2/3 study to further evaluate the safety, tolerability, and immunogenicity of the…
Read More...

Eli Lilly and Company and Rigel Pharmaceuticals, Inc. announced a global exclusive license agreement and strategic collaboration to co-develop and commercialize Rigel's R552, a…
Read More...

Provention Bio, Inc. a biopharmaceutical company dedicated to intercepting and preventing immune-mediated diseases, and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a…
Read More...

Altimmune, Inc. a clinical-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND)…
Read More...

Boston Immune Technologies and Therapeutics, Inc. (BITT), a privately held developer of novel antagonist antibodies for cancer and other diseases, and BeiGene, Ltd. announced that they…
Read More...